ASTA Comments to FDA on Voluntary Sesame Labeling Guidance
ASTA issued comments to the Food and Drug Administration (FDA) in February 2021 on the Voluntary Disclosure of Sesame as an Allergen: Guidance for Industry. Comments outline inconsistencies and confusion arising from the guidance, including that FDA policy already provides that sesame should not be labeled under the generic declaration of spices. ASTA requests that FDA revoke the voluntary guidance due to the legislative process and the FASTER Act.
Membership Required
A valid ASTA membership is required to access this page. Please use the form below to log in with your ASTA member account.
Log in
Not a member yet? Click here to learn about joining ASTA today.
Related Resources
Multi-Industry Letter to RFK Jr. Opposing Cuts to Foodborne Illness Surveillance Program Funding
In November 2025, ASTA signed a Safe Food Coalition letter requesting that Health and Human Services (HHS) Secretary Kennedy fully fund the Centers for Disease Control and Prevention (CDC)’s Foodborne Diseases Active Surveillance Network (FoodNet), the only active foodborne illness surveillance network in the U.S., in response to proposed cuts to the program. The letter was co-signed by both trade associations and public health organizations concerned with this reduction in capacity on active foodborne illness surveillance.
ASTA Comments on FDA Request for Information on Gluten Labeling and Cross-Contact in Packaged Foods
In April 2026, ASTA submitted comments in response to the Food and Drug Administration's (FDA) request for information (RFI) on labeling and cross-contact of gluten in packaged foods, which specifically referenced ingredients that can be declared using collective terms, such as spices. ASTA's comments highlight that no spices inherently contain gluten, note that FDA should take a scientific, risk-based approach to unintended gluten presence, and express support for consistency with existing FDA requirements and harmonization with internal standards for gluten labeling.
